GCD treatment rescues cognitive impairment induced by soluble oligomeric forms of amyloid beta (AβO) as well as protects against AβO-induced hippocampal cell loss. Moreover, GCD inhibits AβO-induced astrogliosis and microgliosis in the hippocampus, and protects against a decline in cholinergic synaptic density in the hippocampus of AβO-injected mice. The gene discussed is ABO; the disease is Cognitive impairment.